Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07071961
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Regorafenib (CT) — DRUG
    Given by po
  • Lorigerlimab — DRUG
    Given by IV

Study Details

To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy

Key Dates

First listed
Jul 18, 2025
Start date
Feb 11, 2026
Status verified
Jun 2026
Primary completion
May 1, 2027
Completion
May 1, 2029

Study Design

Enrollment
16 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: RELO in ctDNA+ mCRC
    receive regorafenib and lorigerlimab for up to 6 months

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Kanwal Raghav, MD
[email protected]
917-733-0356
Kanwal Raghav, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

Nationwide
Colorectal cancer trialsOncology trialsGI oncology trials
By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies